These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 37439782)

  • 1. Tirofiban-induced thrombocytopenia.
    Wang J; Zou D
    Ann Med; 2023 Dec; 55(1):2233425. PubMed ID: 37439782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
    Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH
    Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Unusual Case of Drug-Induced Thrombocytopenia.
    Wang S; Sawalha K; Khan A
    J Investig Med High Impact Case Rep; 2020; 8():2324709620947891. PubMed ID: 32755257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases.
    Abdeladim S; Elharras M; Elouarradi A; Bensahi I; Oualim S; Merzouk F; Sabry M
    Pan Afr Med J; 2021; 38():9. PubMed ID: 33520078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A; Motto C; Abraha I; Cozzolino F; Santilli I
    Cochrane Database Syst Rev; 2014 Mar; (3):CD005208. PubMed ID: 24609741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound thrombocytopenia associated with tirofiban: case report and review of literature.
    Patel S; Patel M; Din I; Reddy CV; Kassotis J
    Angiology; 2005; 56(3):351-5. PubMed ID: 15889207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
    Elcioglu OC; Ozkok A; Akpınar TS; Tufan F; Sezer M; Umman S; Besısık SK
    Int J Hematol; 2012 Sep; 96(3):370-5. PubMed ID: 22767141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of tirofiban.
    Valgimigli M; Tebaldi M
    Expert Opin Drug Saf; 2010 Sep; 9(5):801-19. PubMed ID: 20670206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
    Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
    Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.
    Rahman N; Jafary FH
    Tex Heart Inst J; 2010; 37(1):109-12. PubMed ID: 20200641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
    Brown DL
    Heart; 2003 May; 89(5):535-7. PubMed ID: 12695459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report.
    Demirkan B; Guray Y; Guray U; Korkmaz S
    J Thromb Thrombolysis; 2006 Aug; 22(1):77-8. PubMed ID: 16786237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
    Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
    Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.